Andere talen Amgen Inc. Buenos Aires S.E.

Aandelen

AMGN

ARDEUT110665

slotkoers Buenos Aires S.E. Andere beurzen 00:00:00 19-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13.379 ^ARS	+3,17%		+2,46%	+43,35%

14/06	Amgen Inc. kondigt aan dat de Amerikaanse Food and Drug Administration Blincyto goedkeurt	CI
14/06	Sectorupdate: Aandelen gezondheidszorg vrijdagmiddag zachter	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Amgen : Continues to Propel BiTE® Technology Innovation	15:29
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	14/06
Amgen : Continues to Propel BiTE® Technology Innovation	14/06
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	14/06
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	14/06
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	14/06
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06
Wall Street finit contrastée, nouveaux records pour Nasdaq et S&P 500	13/06
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024	12/06
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub	11/06
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	11/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	06/06
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	05/06
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	05/06
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD	05/06
Amgen's drug meets main goal in late-stage study for rare disease	05/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Amgen Inc. Buenos Aires S.E.

Aandelen

AMGN

ARDEUT110665

Andere talen

Filters